ABBV Oct 2024 220.000 call
OPR - OPR Delayed price. Currency in USD
Add to watchlist
As of 03:14PM EDT. Market open.
| Previous close | 0.2400 |
| Open | 0.3400 |
| Bid | 0.0900 |
| Ask | 0.5000 |
| Strike | 220.00 |
| Expiry date | 2024-10-18 |
| Day's range | 0.2400 - 0.3400 |
| Contract range | N/A |
| Volume | |
| Open interest | 558 |
PR NewswireAbbVie Showcases Advancement of Solid Tumor Pipeline at ESMO 2024, with New Data in Tumor Types with High Unmet Needs
AbbVie (NYSE: ABBV) today announced that new data from its innovative antibody-drug conjugate (ADC) platform will be showcased at the upcoming European Society for Medical Oncology (ESMO) Congress 2024 (September 13-17, 2024). Presentations include data on mirvetuximab soravtansine (ELAHERE®) and c-Met targeting ADCs, telisotuzumab vedotin (Teliso-V) and telisotuzumab adizutecan (ABBV-400). AbbVie's ADCs are designed to target protein biomarkers such as folate receptor-alpha (FRα) and c-Met (MET
- PR Newswire
AbbVie Declares Quarterly Dividend
The board of directors of AbbVie Inc. (NYSE: ABBV) today declared a quarterly cash dividend of $1.55 per share.
Simply Wall St.AbbVie Insiders Sell US$56m Of Stock, Possibly Signalling Caution
The fact that multiple AbbVie Inc. ( NYSE:ABBV ) insiders offloaded a considerable amount of shares over the past year...
© 2024 Yahoo. All rights reserved.